

Efficacy and safety of everolimus for subependymal giant cell astrocytomas in children with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, controlled, phase 3 trial

Lancet, The

381, 125-132

DOI: 10.1016/s0140-6736(12)61134-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	LOW GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i69-i81.	1.2	5
3	Statins in Lymphangioleiomyomatosis. Simvastatin and Atorvastatin Induce Differential Effects on <i>tuberous sclerosis complex 2</i> Null Cell Growth and Signaling. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 704-709.	2.9	29
4	Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex. Current Treatment Options in Neurology, 2013, 15, 618-633.	1.8	29
5	Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Child's Nervous System, 2013, 29, 2301-2305.	1.1	27
6	Role of the mTOR signaling pathway in epilepsy. Journal of the Neurological Sciences, 2013, 332, 4-15.	0.6	101
7	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
8	Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respiratory Medicine, the, 2013, 1, 445-452.	10.7	159
9	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 2013, 31, 3935-3943.	1.6	411
10	mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nature Neuroscience, 2013, 16, 1537-1543.	14.8	316
11	Commentary on: Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-blind, Placebo-controlled Trial. Urology, 2013, 82, 278-279.	1.0	0
12	Everolimus for renal angiomyolipoma in tuberous sclerosis. Lancet, The, 2013, 381, 783-785.	13.7	4
13	Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. European Journal of Paediatric Neurology, 2013, 17, 348-352.	1.6	92
14	Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatric Neurology, 2013, 49, 439-444.	2.1	157
15	Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro-Oncology, 2013, 15, 1604-1614.	1.2	62
16	Is mTOR inhibition a systemic treatment for tuberous sclerosis?. Italian Journal of Pediatrics, 2013, 39, 57.	2.6	46
17	Clinical Neurogenetics. Neurologic Clinics, 2013, 31, 951-968.	1.8	4
18	Everolimus in tuberous sclerosis patients with intractable epilepsy: A treatment option?. European Journal of Paediatric Neurology, 2013, 17, 631-638.	1.6	73
19	Everolimus for astrocytomas in tuberous sclerosis complex. Lancet, The, 2013, 381, 95-96.	13.7	2

#	ARTICLE	IF	CITATIONS
20	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2013, 35, 215-225.	2.5	18
21	Everolimus for astrocytomas in tuberous sclerosis. <i>Lancet</i> , The, 2013, 381, 1274-1275.	13.7	1
22	Everolimus for astrocytomas in tuberous sclerosis – Author's reply. <i>Lancet</i> , The, 2013, 381, 1275.	13.7	9
23	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , The, 2013, 14, e117-e124.	10.7	81
24	Dose-finding designs using a novel quasi-continuous endpoint for multiple-toxicities. <i>Statistics in Medicine</i> , 2013, 32, 2728-2746.	1.6	45
25	mTOR inhibitors as a new therapeutic option for epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 627-638.	2.8	43
26	Progress toward treatments for synaptic defects in autism. <i>Nature Medicine</i> , 2013, 19, 685-694.	30.7	167
27	A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 657-669.	2.8	103
28	Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 167-172.	2.5	16
29	Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. <i>Future Neurology</i> , 2013, 8, 583-597.	0.5	40
30	Everolimus for astrocytoma in tuberous sclerosis complex. <i>Nature Reviews Neurology</i> , 2013, 9, 6-6.	10.1	2
31	Carphology by A Fo Ben. <i>Practical Neurology</i> , 2013, 13, 138-138.	1.1	0
32	New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model. <i>Clinical Cancer Research</i> , 2013, 19, 4553-4558.	7.0	31
33	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	16.0	33
34	Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2013, 74, 679-687.	5.3	332
35	Identifying brain tumours in children and young adults. <i>BMJ</i> , The, 2013, 347, f5844-f5844.	6.0	25
36	Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 14-32.	3.8	74
37	Possible Prevention of Tuberous Sclerosis Complex Lesions. <i>Pediatrics</i> , 2013, 132, e239-e242.	2.1	40

#	ARTICLE	IF	CITATIONS
38	Genetic pathways to autism spectrum disorders. <i>Neuropsychiatry</i> , 2013, 3, 193-207.	0.4	4
39	Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. <i>Biologics: Targets and Therapy</i> , 2013, 7, 211.	3.2	55
40	Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?. <i>PLoS ONE</i> , 2014, 9, e89467.	2.5	8
41	Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2021.	2.2	32
42	Lymphangioliomyomatosis: differential diagnosis and optimal management. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 691.	2.0	23
43	Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer. <i>Epilepsy Currents</i> , 2014, 14, 143-144.	0.8	5
44	Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205138-bcr2014205138.	0.5	23
45	Targeting translation initiation in breast cancer. <i>Translation</i> , 2014, 2, e28968.	2.9	1
46	Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. <i>Child's Nervous System</i> , 2014, 30, 2037-2042.	1.1	45
47	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5564-73.	7.1	355
48	Gene-environment interactions in severe intraventricular hemorrhage of preterm neonates. <i>Pediatric Research</i> , 2014, 75, 241-250.	2.3	49
49	Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1529-1536.	2.4	13
50	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 361-372.	2.4	30
51	mTOR. <i>Neurology</i> , 2014, 83, 1562-1572.	1.1	14
52	Recent advances in pathophysiology studies and treatment of epilepsy in neurocutaneous disorders. <i>Journal of Epileptology</i> , 2014, 22, 99-108.	0.1	0
53	The search for circulating epilepsy biomarkers. <i>Biomarkers in Medicine</i> , 2014, 8, 413-427.	1.4	30
54	mTOR: a new therapeutic target for pediatric low-grade glioma?. <i>CNS Oncology</i> , 2014, 3, 89-91.	3.0	8
55	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. <i>Lancet Oncology</i> , The, 2014, 15, 1513-1520.	10.7	152

#	ARTICLE	IF	CITATIONS
56	The mTOR inhibitor revolution rolls on. <i>Lancet Oncology</i> , The, 2014, 15, 1418-1419.	10.7	4
57	Reply. <i>Annals of Neurology</i> , 2014, 75, 164-165.	5.3	0
58	Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components. <i>Seminars in Cell and Developmental Biology</i> , 2014, 36, 140-146.	5.0	7
59	TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 182.	2.7	62
60	Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. <i>JAMA Dermatology</i> , 2014, 150, 1095.	4.1	93
61	Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. <i>Science Translational Medicine</i> , 2014, 6, 265ra168.	12.4	440
62	Treatment-Related Mortality With Everolimus in Cancer Patients. <i>Oncologist</i> , 2014, 19, 661-668.	3.7	12
63	Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i> -Mutant Cancers. <i>Cancer Discovery</i> , 2014, 4, 1062-1073.	9.4	55
64	Everolimus. Recent Results in Cancer Research, 2014, 201, 373-392.	1.8	54
65	N-of-1 genomic medicine for the rare pediatric genetic diseases. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1279-1290.	0.8	7
66	Clinical utility gene card for: Tuberous sclerosis complex (TSC1, TSC2). <i>European Journal of Human Genetics</i> , 2014, 22, 293-293.	2.8	7
67	Cardiovascular Manifestations of Tuberous Sclerosis Complex and Summary of the Revised Diagnostic Criteria and Surveillance and Management Recommendations From the International Tuberous Sclerosis Consensus Group. <i>Journal of the American Heart Association</i> , 2014, 3, e001493.	3.7	128
68	Treatment of lymphangioleiomyomatosis: building evidence in orphan diseases. <i>European Respiratory Journal</i> , 2014, 43, 966-969.	6.7	5
69	Targeting PI3K/Akt/mTOR Signaling in Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 64.	2.8	1,077
70	Targeting PI3K/mTOR Signaling in Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 84.	2.8	450
71	ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. <i>European Journal of Endocrinology</i> , 2014, 170, R43-R55.	3.7	73
72	Topical Everolimus for Facial Angiofibromas in the Tuberous Sclerosis Complex. A First Case Report. <i>Pediatric Neurology</i> , 2014, 51, 109-113.	2.1	28
73	Natural history and CT scan follow-up of subependymal giant cell tumors in tuberous sclerosis complex patients. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 939-941.	1.5	8

#	ARTICLE	IF	CITATIONS
74	Genetics of rare mesenchymal tumors: Implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa. International Journal of Biochemistry and Cell Biology, 2014, 53, 466-474.	2.8	10
75	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. Journal of Neuro-Oncology, 2014, 117, 7-13.	2.9	15
77	Chemotherapy in Childhood Brain Tumors. Current Pediatrics Reports, 2014, 2, 38-49.	4.0	5
78	Surgical Treatment of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex Patients. Pediatric Neurology, 2014, 50, 307-312.	2.1	58
79	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4
80	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 294-307.	7.4	45
81	Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. Journal of Pediatrics, 2014, 164, 1195-1200.	1.8	139
82	Using genetic findings in autism for the development of new pharmaceutical compounds. Psychopharmacology, 2014, 231, 1063-1078.	3.1	27
83	A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. Journal of Neurosurgery: Pediatrics, 2014, 13, 21-28.	1.3	29
84	Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex:. Journal of Child Neurology, 2014, 29, 1562-1571.	1.4	22
85	Everolimus in Immunosuppressive Treatment After Kidney Transplantation in a Patient With Tuberous Sclerosis: Case Report. Transplantation Proceedings, 2014, 46, 2912-2915.	0.6	6
86	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 833-839.	1.5	87
87	Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly. Current Oncology Reports, 2014, 16, 401.	4.0	9
88	Sustained Effects of Sirolimus on Lung Function and Cystic Lung Lesions in Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1273-1282.	5.6	86
89	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. Journal of Experimental Medicine, 2014, 211, 2249-2263.	8.5	170
90	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation, 2014, 29, 1203-1210.	0.7	79
91	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	2.8	32
92	mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-Oncology, 2014, 16, 493-504.	1.2	67

#	ARTICLE	IF	CITATIONS
94	Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. <i>Journal of Neuro-Oncology</i> , 2014, 118, 205-223.	2.9	31
95	Targeted Therapy in Pediatric Low-Grade Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 441.	4.2	16
96	Molecular Basis of Giant Cells in Tuberous Sclerosis Complex. <i>New England Journal of Medicine</i> , 2014, 371, 778-780.	27.0	47
97	Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. <i>Journal of Neurosurgery</i> , 2014, 120, 331-336.	1.6	23
98	mTOR controls kidney epithelia in health and disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i9-i18.	0.7	48
99	Advances in the Management of Low-Grade Gliomas. <i>Current Oncology Reports</i> , 2014, 16, 398.	4.0	36
100	Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptorâ€‘Positive Advanced Breast Cancer: Considerations for Oncologists. <i>Clinical Breast Cancer</i> , 2014, 14, 297-308.	2.4	24
101	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2014, 87, 104-113.	1.9	28
102	Pharmacologic management of tuberous sclerosis complex-associated subependymal giant cell astrocytomas. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 53-66.	0.8	0
103	Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e448-e451.	0.6	9
104	Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy. <i>Epilepsy & Behavior Case Reports</i> , 2015, 4, 63-66.	1.5	13
105	Retrospective Review of Combined Sirolimus and Simvastatin Therapy in Lymphangioleiomyomatosis. <i>Chest</i> , 2015, 147, 180-187.	0.8	25
106	Everolimus for subependymal giant cell astrocytoma: 5â€‘year final analysis. <i>Annals of Neurology</i> , 2015, 78, 929-938.	5.3	130
107	PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. <i>Scientific Reports</i> , 2015, 5, 14534.	3.3	40
108	Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. <i>Journal of Medical Economics</i> , 2015, 18, 1060-1070.	2.1	31
109	A novel mouse model of Tuberous Sclerosis Complex (TSC): eye-specific <i>Tsc1</i> -ablation disrupts visual pathway development. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1517-29.	2.4	9
110	Cellular and molecular effects of the mTOR inhibitor everolimus. <i>Clinical Science</i> , 2015, 129, 895-914.	4.3	74
112	Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 468-474.	0.6	13

#	ARTICLE	IF	CITATIONS
113	Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. Current Topics in Behavioral Neurosciences, 2015, 28, 1-52.	1.7	100
114	Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis. Orphanet Journal of Rare Diseases, 2015, 10, 95.	2.7	18
115	Successful treatment of kaposiform hemangioendothelioma with everolimus. Pediatric Blood and Cancer, 2015, 62, 536-538.	1.5	38
116	Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. Pediatric Blood and Cancer, 2015, 62, 616-621.	1.5	17
117	Brain Tumor Clinical Trials. Neurosurgery, 2015, 62, 141-145.	1.1	0
118	Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus. Breast Cancer Management, 2015, 4, 129-134.	0.2	1
119	Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis: a case report. Neuropsychiatric Electrophysiology, 2015, 1, .	4.1	13
120	Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis. Pediatric Blood and Cancer, 2015, 62, 798-806.	1.5	26
121	Mammalian target of rapamycin inhibition after solid organ transplantation: <i>can</i> it, and <i>does</i> it, reduce cancer risk?. Clinical Transplantation, 2015, 29, 654-663.	1.6	10
122	Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia, 2015, 56, 1239-1245.	5.1	94
123	Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. Journal of Clinical Pharmacology, 2015, 55, 368-376.	2.0	21
124	Dose-level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma. Pediatric Blood and Cancer, 2015, 62, 1754-1760.	1.5	16
125	Clinical management of tuberous sclerosis complex over the lifetime of a patient. Pediatric Health, Medicine and Therapeutics, 2015, 6, 139.	1.6	8
126	Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. PLoS ONE, 2015, 10, e0127123.	2.5	15
127	Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats. PLoS ONE, 2015, 10, e0135256.	2.5	20
128	The Clinical Characteristics of Subependymal Giant Cell Astrocytoma: Five Cases. Brain Tumor Research and Treatment, 2015, 3, 44.	1.0	15
129	Advances in the treatment of tuberous sclerosis complex. Current Opinion in Psychiatry, 2015, 28, 113-120.	6.3	39
130	Rheb activation disrupts spine synapse formation through accumulation of syntenin in tuberous sclerosis complex. Nature Communications, 2015, 6, 6842.	12.8	31

#	ARTICLE	IF	CITATIONS
131	Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism. <i>Neurotherapeutics</i> , 2015, 12, 572-583.	4.4	47
132	Lymphangiomyomatosis: New Treatment Perspectives. <i>Lung</i> , 2015, 193, 467-475.	3.3	7
133	Neurological and neuropsychiatric aspects of tuberous sclerosis complex. <i>Lancet Neurology</i> , The, 2015, 14, 733-745.	10.2	437
134	Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 433-442.	0.9	7
135	Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014.	1.6	179
136	High-Throughput Drug Screen Identifies Chelerythrine as a Selective Inducer of Death in a TSC2-null Setting. <i>Molecular Cancer Research</i> , 2015, 13, 50-62.	3.4	25
137	Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex. <i>Neurobiology of Disease</i> , 2015, 80, 70-79.	4.4	48
138	Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 626-630.	1.8	18
139	Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 477-486.	2.4	3
140	Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 274-281.	2.0	41
141	Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 259-273.	2.0	96
142	Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 282-294.	2.0	16
143	Establishment of Tsc2-deficient rat embryonic stem cells. <i>International Journal of Oncology</i> , 2015, 46, 1944-1952.	3.3	4
144	The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent. <i>Pediatric Nephrology</i> , 2015, 30, 173-177.	1.7	12
145	Use of mTOR Inhibitor Everolimus in Three Neonates for Treatment of Tumors Associated With Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2015, 52, 450-453.	2.1	60
147	Hereditary Predisposition to Primary CNS Tumors. <i>Molecular Pathology Library</i> , 2015, , 1-22.	0.1	0
149	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 823-834.	3.3	3
150	Congenital focal lymphedema as a diagnostic clue to tuberous sclerosis complex: report of two cases diagnosed by ultrasound. <i>Skeletal Radiology</i> , 2015, 44, 1165-1168.	2.0	10

#	ARTICLE	IF	CITATIONS
151	mTOR Inhibition in Epilepsy: Rationale and Clinical Perspectives. <i>CNS Drugs</i> , 2015, 29, 91-99.	5.9	80
152	Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy. <i>Pediatric Neurology</i> , 2015, 52, 281-289.	2.1	117
153	Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 313-320.	2.9	87
154	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 58-64.	1.2	111
155	Autophagy and amino acid metabolism in the brain: implications for epilepsy. <i>Amino Acids</i> , 2015, 47, 2113-2126.	2.7	23
156	The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations. <i>Journal of Neural Transmission</i> , 2015, 122, 849-862.	2.8	50
157	A rapid and high content assay that measures cyto-ID-stained autophagic compartments and estimates autophagy flux with potential clinical applications. <i>Autophagy</i> , 2015, 11, 560-572.	9.1	121
158	Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature. <i>Pediatric Neurology</i> , 2015, 53, 23-30.	2.1	26
159	mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. <i>Transplantation Reviews</i> , 2015, 29, 168-174.	2.9	56
160	Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma. <i>American Journal of Roentgenology</i> , 2015, 205, 292-301.	2.2	20
162	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. <i>European Journal of Human Genetics</i> , 2015, 23, 1665-1672.	2.8	29
163	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. <i>Neurobiology of Disease</i> , 2015, 82, 22-31.	4.4	14
164	Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11055-11086.	4.1	104
165	Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. <i>Haematologica</i> , 2015, 100, 541-547.	3.5	34
166	Tuberous sclerosis complex. <i>Paediatrics and Child Health (United Kingdom)</i> , 2015, 25, 467-473.	0.4	2
167	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 847-858.	2.4	15
168	Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. <i>European Respiratory Journal</i> , 2015, 46, 783-794.	6.7	83
169	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	2.4	22

#	ARTICLE	IF	CITATIONS
170	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	1.2	178
171	Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma. <i>Brain and Development</i> , 2015, 37, 553-562.	1.1	72
172	Role of mTOR inhibitors in epilepsy treatment. <i>Pharmacological Reports</i> , 2015, 67, 636-646.	3.3	43
173	Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus. <i>Acta Neurochirurgica</i> , 2015, 157, 241-245.	1.7	7
174	Remarkable improvement of selective mutism with everolimus in a patient with tuberous sclerosis complex. <i>Acta Neurologica Belgica</i> , 2015, 115, 815-817.	1.1	1
175	Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. <i>BMC Medical Genetics</i> , 2015, 16, 10.	2.1	62
176	Pediatric Neuro-oncology. , 2015, , .		2
177	Tuberous Sclerosis Complex. <i>Pediatric Clinics of North America</i> , 2015, 62, 633-648.	1.8	119
178	Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. <i>Anti-Cancer Drugs</i> , 2015, 26, 437-442.	1.4	49
179	Structural MRI biomarkers of shared pathogenesis in autism spectrum disorder and epilepsy. <i>Epilepsy and Behavior</i> , 2015, 47, 172-182.	1.7	18
180	Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients. <i>Cancer Investigation</i> , 2015, 33, 70-77.	1.3	27
181	Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 619-630.	1.9	25
182	mTOR inhibitors and diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 101-108.	2.8	86
183	The changing face of a rare disease: lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2015, 46, 1471-1485.	6.7	45
184	Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. <i>Journal of Medical Economics</i> , 2015, 18, 349-356.	2.1	6
185	Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2015, 30, 1192-1195.	1.4	8
186	New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth. <i>Rare Diseases (Austin, Tex)</i> , 2015, 3, e1016701.	1.8	4
187	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. <i>Pediatric Neurology</i> , 2015, 53, 238-242.e1.	2.1	6

#	ARTICLE	IF	CITATIONS
188	Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. <i>Neuro-Oncology</i> , 2015, 17, 1550-1559.	1.2	123
189	Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?. <i>Current Oncology Reports</i> , 2015, 17, 46.	4.0	6
190	Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 802-808.	1.2	43
191	Complications of hyperglycaemia with PI3Kâ€“AKTâ€“mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. <i>British Journal of Cancer</i> , 2015, 113, 1541-1547.	6.4	30
192	Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 79-90.	2.4	15
194	Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist. <i>Pediatric Neurology</i> , 2015, 52, 25-35.	2.1	229
195	mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, 1086-1095.	2.7	53
196	The mTOR signaling pathway as a treatment target for intracranial neoplasms. <i>Neuro-Oncology</i> , 2015, 17, 189-199.	1.2	44
197	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
198	Incidence and risk of rash to mTOR inhibitors in cancer patients â€“ a meta-analysis of randomized controlled trials. <i>Acta OncolÃ³gica</i> , 2015, 54, 124-132.	1.8	9
199	Everolimus-associated stomatitis in a patient who had renal transplant. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217513.	0.5	6
200	Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2165-2172.	2.2	17
201	New advances in targeted gastric cancer treatment. <i>World Journal of Gastroenterology</i> , 2016, 22, 6776.	3.3	74
202	mTOR Signaling in Epilepsy and Epileptogenesis. , 2016, , 123-142.		4
203	Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. <i>Journal of Transplantation</i> , 2016, 2016, 1-11.	0.5	43
204	Targeted Therapies for Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1543.	4.1	67
205	Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?. <i>Journal of Cancer</i> , 2016, 7, 1621-1631.	2.5	24
206	Neurocutaneous syndromes. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 565-589.	1.8	19

#	ARTICLE	IF	CITATIONS
207	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet Journal of Rare Diseases, 2016, 11, 128.	2.7	11
208	Rapid Regression of Cardiac Rhabdomyoma after Everolimus Administration in an Infant with Tuberous Sclerosis. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2016, 32, 251-256.	0.0	1
209	Targeted treatment of tuberous sclerosis complex in Egyptian children. Middle East Journal of Medical Genetics, 2016, 5, 31-36.	0.0	0
210	Systemic effects of treatment with <scp>mTOR</scp> inhibitors in tuberous sclerosis complex: a comprehensive review. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 586-594.	2.4	26
211	Efficacy and safety of Everolimus in children with TSC - associated epilepsy â€“ Pilot data from an open single-center prospective study. Orphanet Journal of Rare Diseases, 2016, 11, 145.	2.7	47
212	The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials, 2016, 17, 398.	1.6	11
213	Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. Therapeutic Drug Monitoring, 2016, 38, 663-669.	2.0	12
214	EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. BMC Neurology, 2016, 16, 126.	1.8	15
215	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	2.0	102
216	New Indications of mTOR Inhibitors in Rare Tumors. , 2016, , 113-137.		0
217	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
218	mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacological Research, 2016, 107, 333-343.	7.1	144
219	Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1360-1367.	0.7	34
220	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs, 2016, 76, 551-565.	10.9	66
221	Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial. Journal of Pediatrics, 2016, 172, 151-155.e1.	1.8	29
222	Tuberous Sclerosis Health Care Utilization Based on the National Inpatient Sample Database: A Review of 5655 Hospitalizations. World Neurosurgery, 2016, 91, 97-105.	1.3	10
223	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. Journal of Neuro-Oncology, 2016, 128, 293-302.	2.9	51
224	Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complexâ€”A Comprehensive Review of the Literature. Pediatric Neurology, 2016, 61, 21-27.	2.1	31

#	ARTICLE	IF	CITATIONS
225	Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. <i>Nephron</i> , 2016, 134, 51-58.	1.8	58
226	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet</i> , The, 2016, 388, 2153-2163.	13.7	554
227	Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture. <i>Pediatric Neurology</i> , 2016, 63, 6-22.	2.1	44
228	Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model. <i>Genome Medicine</i> , 2016, 8, 94.	8.2	37
229	Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 129.	2.7	20
230	Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas. <i>Child's Nervous System</i> , 2016, 32, 1939-1945.	1.1	4
231	mTORC1 inhibition for epilepsy in TSC. <i>Neurology</i> , 2016, 87, 974-975.	1.1	1
232	Sirolimus for epilepsy in children with tuberous sclerosis complex. <i>Neurology</i> , 2016, 87, 1011-1018.	1.1	73
233	Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile. <i>Pharmacological Reports</i> , 2016, 68, 1002-1007.	3.3	2
234	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. <i>Oncologist</i> , 2016, 21, 1326-1336.	3.7	49
235	Towards a Molecular Syndromology of the Epilepsies. <i>Molecular Syndromology</i> , 2016, 7, 169-171.	0.8	0
236	Low-Grade Gliomas. , 2016, , 452-468.e3.		1
237	Genotype and brain pathology phenotype in children with tuberous sclerosis complex. <i>European Journal of Human Genetics</i> , 2016, 24, 1688-1695.	2.8	35
238	Rapamycin and rapalogs for tuberous sclerosis complex. <i>The Cochrane Library</i> , 2017, 2017, CD011272.	2.8	33
239	Tuberous sclerosis complex. <i>Neurology: Clinical Practice</i> , 2016, 6, 339-347.	1.6	8
240	Recommendations for the multidisciplinary management of tuberous sclerosis complex. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 211-216.	0.2	2
241	Long-term treatment of epilepsy with everolimus in tuberous sclerosis. <i>Neurology</i> , 2016, 87, 2408-2415.	1.1	130
242	Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. <i>Cancer Investigation</i> , 2016, 34, 521-530.	1.3	24

#	ARTICLE	IF	CITATIONS
243	mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology. Current Neurology and Neuroscience Reports, 2016, 16, 102.	4.2	24
244	Tuberous sclerosis complex. Nature Reviews Disease Primers, 2016, 2, 16035.	30.5	473
245	Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Therapeutic Advances in Urology, 2016, 8, 279-290.	2.0	39
246	Severe pneumonia by Mycoplasma as an adverse event of everolimus therapy in patients with tuberous sclerosis complex. European Journal of Paediatric Neurology, 2016, 20, 758-760.	1.6	5
249	The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD). Journal of Medical Economics, 2016, 19, 1116-1126.	2.1	13
250	Cutaneous and ocular manifestations of neurocutaneous syndromes. Clinics in Dermatology, 2016, 34, 183-204.	1.6	23
251	Exploring novel AEDs from drugs used for treatment of non-epileptic disorders. Expert Review of Neurotherapeutics, 2016, 16, 449-461.	2.8	9
252	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2016, 141, 43-48.	1.4	21
253	Rare glial tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 399-415.	1.8	10
254	Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. Pediatric Blood and Cancer, 2016, 63, 1276-1278.	1.5	4
255	Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacological Reports, 2016, 68, 536-542.	3.3	47
256	mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. Expert Review of Respiratory Medicine, 2016, 10, 249-260.	2.5	20
257	Advances in Tuberous Sclerosis Complex (TSC) research. Advances in Autism, 2016, 2, 59-69.	1.0	1
258	Toward targeted treatments in tuberous sclerosis. Expert Opinion on Orphan Drugs, 2016, 4, 243-253.	0.8	1
259	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). Urology, 2016, 89, 19-26.	1.0	23
260	Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of Oncology, 2016, 27, 519-525.	1.2	68
261	Cross-sectional Imaging Review of Tuberous Sclerosis. Radiologic Clinics of North America, 2016, 54, 423-440.	1.8	20
262	Developing therapies for rare tumors: opportunities, challenges and progress. Expert Opinion on Orphan Drugs, 2016, 4, 93-103.	0.8	5

#	ARTICLE	IF	CITATIONS
263	mTOR Inhibition for Cancer Therapy: Past, Present and Future. , 2016, , .		3
264	The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clinical, 2016, 5, 29-40.	4.1	34
265	Early rescue of interneuron disease trajectory in developmental epilepsies. Current Opinion in Neurobiology, 2016, 36, 82-88.	4.2	4
266	Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World Journal of Biological Psychiatry, 2016, 17, 174-186.	2.6	148
267	Neurocutaneous Syndromes and Brain Tumors. Journal of Child Neurology, 2016, 31, 1399-1411.	1.4	15
268	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology Dialysis Transplantation, 2016, 31, 111-119.	0.7	120
269	Genetic animal models of malformations of cortical development and epilepsy. Journal of Neuroscience Methods, 2016, 260, 73-82.	2.5	38
270	Current and future strategies for treatment of glioma. Neurosurgical Review, 2017, 40, 1-14.	2.4	416
271	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (<scp>EILAT XIII</scp>). Epilepsia, 2017, 58, 181-221.	5.1	92
272	Treatment of Lymphangioleiomyomatosis (LAM). Milestones in Drug Therapy, 2017, , 239-263.	0.1	0
273	Persistent Hepatitis E Infection in a Patient with Tuberous Sclerosis Complex Treated with Everolimus: A Case Report. Infectious Diseases and Therapy, 2017, 6, 291-295.	4.0	4
274	Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study. Geburtshilfe Und Frauenheilkunde, 2017, 77, 66-72.	1.8	15
275	Asbestos and Mesothelioma. Current Cancer Research, 2017, , .	0.2	5
276	Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. Pediatric Neurology, 2017, 72, 81-85.	2.1	17
277	Hereditary Renal Cystic Disorders: Imaging of the Kidneys and Beyond. Radiographics, 2017, 37, 924-946.	3.3	29
278	Chordoma Occurs in Young Children With Tuberous Sclerosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 418-423.	1.7	10
279	Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence. Modern Pathology, 2017, 30, 318-328.	5.5	18
280	Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist, 2017, 22, 655-666.	3.7	7

#	ARTICLE	IF	CITATIONS
281	Cancer and mTOR Inhibitors in Transplant Recipients. Transplantation, 2017, 101, 45-55.	1.0	104
282	Diffuse Lung Cysts in a Man with Polycystic Kidney Disease. Annals of the American Thoracic Society, 2017, 14, 795-798.	3.2	2
283	Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. Journal of Pediatrics, 2017, 187, 318-322.e2.	1.8	22
284	TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells. Human Molecular Genetics, 2017, 26, 3303-3312.	2.9	16
285	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an <i>STK11</i> variant. Journal of Physical Education and Sports Management, 2017, 3, a000778.	1.2	20
286	Targeted Treatment of Brain Metastases. Current Neurology and Neuroscience Reports, 2017, 17, 37.	4.2	28
287	Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. Orphanet Journal of Rare Diseases, 2017, 12, 35.	2.7	57
288	Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role. Archives of Disease in Childhood, 2017, 102, 858-863.	1.9	40
289	mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet Journal of Rare Diseases, 2017, 12, 51.	2.7	38
290	Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1196-1202.	4.5	24
291	Loss of Nardilysin, a Mitochondrial Co-chaperone for α -Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration. Neuron, 2017, 93, 115-131.	8.1	95
292	Manifestations of Tuberous Sclerosis Complex: The Experience of a Provincial Clinic. Canadian Journal of Neurological Sciences, 2017, 44, 35-43.	0.5	15
293	Advances in the molecular genetics of gliomas – implications for classification and therapy. Nature Reviews Clinical Oncology, 2017, 14, 434-452.	27.6	497
294	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
296	New insights in lymphangiomyomatosis and pulmonary Langerhans cell histiocytosis. European Respiratory Review, 2017, 26, 170042.	7.1	28
297	Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD). BMJ Open, 2017, 7, e015236.	1.9	22
298	Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability. Nature Communications, 2017, 8, 1052.	12.8	63
299	Implementing a Multidisciplinary Approach to Treating Tuberous Sclerosis Complex. Child Neurology Open, 2017, 4, 2329048X1772560.	1.1	4

#	ARTICLE	IF	CITATIONS
300	Everolimus for the Treatment of Tuberous Sclerosis Complex-Related Cardiac Rhabdomyomas in Pediatric Patients. <i>Journal of Pediatrics</i> , 2017, 190, 21-26.e7.	1.8	34
301	mTOR-related neuropathology in mutant tsc2 zebrafish: Phenotypic, transcriptomic and pharmacological analysis. <i>Neurobiology of Disease</i> , 2017, 108, 225-237.	4.4	29
302	Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions. <i>Journal of Pediatric Neurology</i> , 2017, 15, 134-142.	0.2	3
303	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
304	Tuberous sclerosis complex: Recent advances in manifestations and therapy. <i>International Journal of Urology</i> , 2017, 24, 681-691.	1.0	47
305	Target and Agent Prioritization for the Children's Oncology Group National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85
306	A vicious partnership between <scp>AKT</scp> and <scp>PHLDA</scp>3 to facilitate neuroendocrine tumors. <i>Cancer Science</i> , 2017, 108, 1101-1108.	3.9	20
307	Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases. <i>Pediatric Cardiology</i> , 2017, 38, 1478-1484.	1.3	29
308	Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , 2017, 35, 552-561.	1.3	5
309	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. <i>Clinical Cancer Research</i> , 2017, 23, 6958-6968.	7.0	74
310	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
311	Addressing the challenges of lymphangioleiomyomatosis assessment in the clinic. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 953-965.	0.8	0
312	Optimized care in Patients with Rare Diseases: TSC at the Center for Rare Diseases (ZSEUKS) at Saarland University Medical Center, Germany. <i>Klinische Padiatrie</i> , 2017, 229, 311-315.	0.6	3
313	Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 877-887.	3.7	92
314	The genomic landscape of tuberous sclerosis complex. <i>Nature Communications</i> , 2017, 8, 15816.	12.8	154
315	Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). <i>Metabolomics</i> , 2017, 13, 98.	3.0	12
316	Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 383-388.	1.3	56
317	Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex. <i>JAMA Dermatology</i> , 2017, 153, 39.	4.1	84

319	Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatric Blood and Cancer, 2017, 64, e26288.	1.5	71
320	Upregulation of cystathione ð€synthase and p7OS6K/S6 in neonatal hypoxic ischemic brain injury. Brain Pathology, 2017, 27, 449-458.	4.1	16
322	Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Pediatric Nephrology, 2017, 32, 1137-1144.	1.7	27
323	A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatric Blood and Cancer, 2017, 64, e26258.	1.5	12
324	Neurocutaneous Syndromes and Associated CNS Tumors. Pediatric Oncology, 2017, , 237-271.	0.5	0
325	Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex. Pediatric Cardiology, 2017, 38, 394-400.	1.3	50
327	Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. Brain Tumor Research and Treatment, 2017, 5, 37.	1.0	13
328	Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	38
329	mTOR-Dependent Cell Proliferation in the Brain. BioMed Research International, 2017, 2017, 1-14.	1.9	70
330	Toward a Better Understanding of the Use of Targeted Therapies in Pediatric Sarcoma Patients. Journal of Pediatric Biochemistry, 2017, 06, 119-120.	0.2	0
331	9 Malformations and Developmental Abnormalities. , 2017, , .		0
332	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE, 2017, 12, e0180939.	2.5	128
333	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. Journal of Clinical Oncology, 2017, 35, 2370-2377.	1.6	223
334	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	27.6	762
335	Drug discovery targeting the mTOR pathway. Clinical Science, 2018, 132, 543-568.	4.3	65
336	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) Tj ETQqO O O gBT /Overlock 10	0.6	1
337	Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4â€year results from the randomized <sc>EXIST</sc>â€1 and <sc>EXIST</sc>â€2 studies. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1796-1803	2.4	26

#	ARTICLE	IF	CITATIONS
339	Tuberous sclerosis complex: Concerns and needs of patients and parents from the transitional period to adulthood. <i>Epilepsy and Behavior</i> , 2018, 83, 13-21.	1.7	33
340	Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002220.	1.2	16
341	Efficacy and safety of everolimus in patients younger than 12 months with congenital subependymal giant cell astrocytoma. <i>Brain and Development</i> , 2018, 40, 415-420.	1.1	13
342	Spontaneous reduction of native kidney size involving angiomyolipoma lesions in a kidney transplant recipient with tuberous sclerosis complex. <i>International Journal of Urology</i> , 2018, 25, 513-514.	1.0	3
343	The essential symbiosis of academic and clinical neurology. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 5-5.	2.1	0
344	Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus. <i>Journal of AAPOS</i> , 2018, 22, 76-79.	0.3	12
345	Rapid regression of large cardiac rhabdomyomas in neonates after sirolimus therapy. <i>Cardiology in the Young</i> , 2018, 28, 485-489.	0.8	18
346	Recombinant human erythropoietin protects against brain injury through blunting the mTORC1 pathway in the developing brains of rats with seizures. <i>Life Sciences</i> , 2018, 194, 15-25.	4.3	9
348	Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 43.	2.7	24
349	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.8	2
350	Everolimus dosing recommendations for <scp>tuberous sclerosis complex</scp>-associated refractory seizures. <i>Epilepsia</i> , 2018, 59, 1188-1197.	5.1	41
351	Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use – Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2018, 50, 1904-1909.	0.6	5
352	Oral stomatitis and <scp>mTOR</scp> inhibitors: A review of current evidence in 20,915 patients. <i>Oral Diseases</i> , 2018, 24, 144-171.	3.0	18
353	Diagnosis and Treatment of Tuberous Sclerosis Manifestations in Children: A Multicenter Study. <i>Neuropediatrics</i> , 2018, 49, 193-199.	0.6	5
354	Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. <i>Neurochirurgie</i> , 2018, 64, 370-374.	1.2	21
355	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 53-61.	2.6	15
356	Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. <i>Toxicology in Vitro</i> , 2018, 46, 229-236.	2.4	13
357	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. <i>Pediatric Nephrology</i> , 2018, 33, 101-109.	1.7	37

#	ARTICLE	IF	CITATIONS
358	Precision Medicine in Pediatric Neurooncology: A Review. ACS Chemical Neuroscience, 2018, 9, 11-28.	3.5	12
359	The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. Reviews in the Neurosciences, 2018, 29, 295-301.	2.9	17
360	Management of the "Other" retroperitoneal sarcomas. Journal of Surgical Oncology, 2018, 117, 79-86.	1.7	16
361	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight, 2018, 3, .	5.0	49
362	Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. Epilepsia Open, 2018, 3, 180-190.	2.4	13
363	Predisposition Syndromes to Central Nervous System Cancers. , 2018, , 91-116.		0
364	The use of rapamycin in patients with tuberous sclerosis complex: Long-term results. Epilepsy and Behavior, 2018, 88, 357-364.	1.7	10
365	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
366	mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 365-373.	1.6	44
367	Central nervous system manifestations of tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 291-298.	1.6	36
368	Renal disease in tuberous sclerosis complex: pathogenesis and therapy. Nature Reviews Nephrology, 2018, 14, 704-716.	9.6	83
369	Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. JAMA Dermatology, 2018, 154, 781.	4.1	44
370	Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex. Child's Nervous System, 2018, 34, 1511-1519.	1.1	12
371	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	5.6	77
372	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	2.5	40
373	Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Modern Pathology, 2018, 31, 1787-1800.	5.5	24
374	Thoracoabdominal imaging of tuberous sclerosis. Pediatric Radiology, 2018, 48, 1307-1323.	2.0	7
375	Tuberous sclerosis complex: review based on new diagnostic criteria. Anais Brasileiros De Dermatologia, 2018, 93, 323-331.	1.1	81

#	ARTICLE	IF	CITATIONS
376	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	2.8	123
377	Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. <i>Pediatric Nephrology</i> , 2018, 33, 2085-2093.	1.7	29
378	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 1066-1073.	1.6	54
379	mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1474.	4.1	20
380	Population pharmacokinetics and pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 707-719.	1.8	10
381	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	2.6	18
382	Expert opinion on the metabolic complications of mTOR inhibitors. <i>Annales D'Endocrinologie</i> , 2018, 79, 583-590.	1.4	8
383	A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2018, 178, 309-320.	1.6	71
384	Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 196-200.	1.0	11
385	The mTOR pathway in treatment of epilepsy: a clinical update. <i>Future Neurology</i> , 2018, 13, 49-58.	0.5	47
386	Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. <i>Brain and Development</i> , 2019, 41, 1-10.	1.1	60
387	The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives. <i>Epilepsy and Behavior</i> , 2019, 91, 94-98.	1.7	33
388	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1000-1008.	0.7	31
389	Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. <i>Journal of Investigative Medicine</i> , 2019, 67, 39-47.	1.6	10
390	mTOR: Role in cancer, metastasis and drug resistance. <i>Seminars in Cancer Biology</i> , 2019, 59, 92-111.	9.6	299
391	Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RAR β). <i>Oncogene</i> , 2019, 38, 7367-7383.	5.9	11
392	<p></p>Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives</p>. <i>Eye and Brain</i> , 2019, Volume 11, 13-23.	2.5	13
393	Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis. <i>AJP Reports</i> , 2019, 09, e213-e217.	0.7	15

#	ARTICLE	IF	CITATIONS
394	Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. Expert Review of Neurotherapeutics, 2019, 19, 913-925.	2.8	33
395	Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders. Handbook of Behavioral Neuroscience, 2019, , 309-331.	0.7	2
396	A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology, 2019, 93, e200-e209.	1.1	78
397	Biallelic Mutations in <i>TSC2</i> Lead to Abnormalities Associated with Cortical Tubers in Human iPSC-Derived Neurons. Journal of Neuroscience, 2019, 39, 9294-9305.	3.6	60
398	The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma. Journal of Translational Medicine, 2019, 17, 354.	4.4	10
399	Phakomatoses. Dermatologic Clinics, 2019, 37, 583-606.	1.7	8
400	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. Journal of Experimental Medicine, 2019, 216, 2635-2652.	8.5	20
401	Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy. Scientific Reports, 2019, 9, 14337.	3.3	9
402	The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy, 2019, 7, 1-32.	2.6	19
403	Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. Journal of Dermatological Science, 2019, 94, 350-353.	1.9	5
404	Concepts of Personalized Medicine in Neuro-oncology. , 2019, , 153-158.		0
405	Successful treatment of a <i>TSC2</i> -mutant glioblastoma with everolimus. BMJ Case Reports, 2019, 12, e227734.	0.5	14
406	Selumetinib in paediatric low-grade glioma: a new era?. Lancet Oncology, The, 2019, 20, 900-901.	10.7	1
407	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer. International Journal of Biological Sciences, 2019, 15, 929-941.	6.4	21
408	Diagnostic Yields of Trio-WES Accompanied by CNVseq for Rare Neurodevelopmental Disorders. Frontiers in Genetics, 2019, 10, 485.	2.3	28
409	Neuro-oncology. , 2019, , 391-457.		0
410	Tuberous Sclerosis Complex. , 2019, , 369-377.		0
411	Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. Journal of Pharmaceutical Health Care and Sciences, 2019, 5, 6.	1.0	6

#	ARTICLE	IF	CITATIONS
412	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. <i>Drug Safety</i> , 2019, 42, 813-825.	3.2	78
413	Molecular genetics and therapeutic targets of pediatric low-grade gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 74-83.	1.7	19
414	The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders. <i>Clinical Genetics</i> , 2019, 96, 140-150.	2.0	30
415	Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of everolimus use with diabetes. <i>Endocrine Journal</i> , 2019, 66, 571-574.	1.6	10
416	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i> -Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	7.0	57
417	Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 39.	2.7	58
418	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980.	1.2	52
419	Dynamic thiol/disulphide homeostasis in children with neurofibromatosis type 1 and tuberous sclerosis. <i>Acta Neurologica Belgica</i> , 2019, 119, 419-422.	1.1	3
420	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 386-396.	27.6	39
421	Precision medicine for pediatric central nervous system tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 55-57.	0.7	1
422	The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex. <i>Journal of Neurodevelopmental Disorders</i> , 2019, 11, 30.	3.1	38
423	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. <i>Frontiers in Neurology</i> , 2019, 10, 1116.	2.4	11
424	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. <i>Annual Review of Genetics</i> , 2019, 53, 483-503.	7.6	22
425	Neurological malignancies in neurofibromatosis type 1. <i>Current Opinion in Oncology</i> , 2019, 31, 554-561.	2.4	5
427	Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. <i>Current Medical Research and Opinion</i> , 2019, 35, 1103-1110.	1.9	4
428	Lymphangiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2019, 16, 509-512.	3.2	9
429	<i>CD79B</i> mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. <i>European Journal of Haematology</i> , 2019, 102, 191-196.	2.2	52
430	Tuberous sclerosis complex: new insights into clinical and therapeutic approach. <i>Journal of Nephrology</i> , 2019, 32, 355-363.	2.0	19

#	ARTICLE	IF	CITATIONS
431	The UK guidelines for management and surveillance of Tuberous Sclerosis Complex. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 171-182.	0.5	26
432	Intracellular Signaling. , 2020, , 24-46.e12.		0
433	Genetics of Common Pediatric Brain Tumors. Pediatric Neurology, 2020, 104, 3-12.	2.1	14
434	Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 2020, 77, 1745-1770.	5.4	927
435	Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Paediatric Drugs, 2020, 22, 73-84.	3.1	44
436	Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients. Child's Nervous System, 2020, 36, 951-960.	1.1	14
437	The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas. Brain, 2020, 143, 131-149.	7.6	24
438	Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells. Pharmaceuticals, 2020, 13, 419.	3.8	6
439	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. Frontiers in Immunology, 2020, 11, 1423.	4.8	5
440	The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC). Frontiers in Neuroanatomy, 2020, 14, 39.	1.7	35
441	Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2020, 15, 209.	2.7	4
442	Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. Diagnostics, 2020, 10, 582.	2.6	21
443	Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex. Respiratory Medicine Case Reports, 2020, 31, 101310.	0.4	3
444	Tuberous sclerosis: a review of the past, present, and future. Turkish Journal of Medical Sciences, 2020, 50, 1665-1676.	0.9	42
445	mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. Radiology Imaging Cancer, 2020, 2, e190091.	1.6	1
446	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Letters, 2020, 485, 1-13.	7.2	10
447	Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial. Dermatology and Therapy, 2020, 10, 635-650.	3.0	17
448	Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 20-26.	2.0	32

#	ARTICLE	IF	CITATIONS
449	Model-Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 230-237.	2.5	11
450	Neurocutaneous disorders. , 2020, , 1-26.		1
451	An Overview of Pediatric CNS Malignancies. , 0, , .		1
452	Long-term use of mTORC1 inhibitors in tuberous sclerosis complex associated neurological aspects. Expert Opinion on Orphan Drugs, 2020, 8, 215-225.	0.8	1
453	Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex. Urology, 2020, 139, 161-167.	1.0	3
454	Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everolimus for cardiac rhabdomyomas in tuberous sclerosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial. Cardiology in the Young, 2020, 30, 337-345.	0.8	14
455	Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). Expert Opinion on Pharmacotherapy, 2020, 21, 1329-1336.	1.8	20
456	The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Journal of Neuro-Oncology, 2020, 147, 731-736.	2.9	8
457	Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1 α pathway suppression. Nature Communications, 2020, 11, 1869.	12.8	129
458	Detection of endophenotypes associated with neuropsychiatric deficiencies in a mouse model of tuberous sclerosis complex using diffusion tensor imaging. Brain Pathology, 2021, 31, 4-19.	4.1	6
459	Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis. Cardiology in the Young, 2021, 31, 312-314.	0.8	4
460	Stereotactic guided ablation for subependymal giant cell astrocytomas: does it change the surgical indications?. Child's Nervous System, 2021, 37, 735-736.	1.1	2
461	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatric Blood and Cancer, 2021, 68, e28787.	1.5	17
462	Clinical Utility of Next-Generation Sequencing for Developmental Disorders in the Rehabilitation Department: Experiences from a Single Chinese Center. Journal of Molecular Neuroscience, 2021, 71, 845-853.	2.3	5
463	Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. Epilepsy and Behavior, 2022, 131, 107713.	1.7	10
464	Hemimegalencephaly and tuberous sclerosis complex: A rare yet challenging association. European Journal of Paediatric Neurology, 2021, 30, 58-65.	1.6	9
465	Approach to the patient with tuberous sclerosis. , 2021, , 229-241.		0
467	Current Approaches and Future Directions for the Treatment of mTORopathies. Developmental Neuroscience, 2021, 43, 143-158.	2.0	40

#	ARTICLE	IF	CITATIONS
468	Bibliometric analysis of the top 100 most-cited articles on astrocytoma. , 2021, 12, 62.		2
469	Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study. Epilepsia, 2021, 62, 785-794.	5.1	12
470	The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial. EClinicalMedicine, 2021, 32, 100715.	7.1	13
471	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2021, 27, 2442-2451.	7.0	13
472	TuberOus Sclerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	2.4	10
473	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research, 2021, 27, 3845-3853.	7.0	25
474	mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. Journal of Neurodevelopmental Disorders, 2021, 13, 14.	3.1	17
475	Tuberous Sclerosis Complex. Seminars in Pediatric Neurology, 2021, 37, 100875.	2.0	13
476	Subependymal Giant Cell Astrocytomas (SEGAs): a Model of Targeting Tumor Growth and Epilepsy. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	0
477	Innumerable Meningiomas Arising in a Patient With Tuberous Sclerosis Complex Decades After Radiation Therapy. Pediatric and Developmental Pathology, 2021, 24, 471-477.	1.0	1
478	Pediatric Gliomas. Neurosurgery Clinics of North America, 2021, 32, 181-190.	1.7	6
480	The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation. International Journal of Molecular Sciences, 2021, 22, 4116.	4.1	3
481	Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis â€“ Final Results From the EMINENTS Study. Frontiers in Neurology, 2021, 12, 581102.	2.4	12
482	Angiomiolipoma renal y complejo esclerosis tuberosa: resultados a largo plazo en seguridad y eficacia de terapia con everolimus. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 264-272.	0.7	2
483	Clinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis. Orphanet Journal of Rare Diseases, 2021, 16, 243.	2.7	6
484	Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 264-272.	0.2	0
485	Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Frontiers in Endocrinology, 2021, 12, 678869.	3.5	3
486	Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complexâ€”A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 4907.	2.6	22

#	ARTICLE	IF	CITATIONS
487	Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 1707-1715.	2.6	4
488	New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6802.	4.1	1
489	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591.	4.1	11
490	High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients. <i>Transplant International</i> , 2021, 34, 1293-1305.	1.6	5
491	Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6677.	4.1	15
492	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. <i>Current Problems in Cancer</i> , 2022, 46, 100776.	2.0	7
493	Renal neoplasms in tuberous sclerosis mice are neurocristopathies. <i>IScience</i> , 2021, 24, 102684.	4.1	6
494	Effectiveness of targeted therapy for kidney damage with tuberous sclerosis in a child (clinical case). <i>Nephrology (Saint-Petersburg)</i> , 2021, 25, 90-94.	0.4	0
495	Targeted Therapies in Rare Brain Tumours. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7949.	4.1	4
497	Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 299.	2.7	5
498	Novel Treatments and Clinical Research in Child Neurology. <i>Neurologic Clinics</i> , 2021, 39, 719-722.	1.8	0
499	Pediatric Neuro-Oncology. <i>Neurologic Clinics</i> , 2021, 39, 829-845.	1.8	12
500	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003732.	8.4	38
501	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
502	Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. <i>Frontiers in Oncology</i> , 2021, 11, 719623.	2.8	5
503	Sclerosi tuberosa ed everolimus: una nuova storia. <i>Medico E Bambino</i> , 2021, 40, 443-449.	0.1	0
504	Epilepsy in the mTORopathies: opportunities for precision medicine. <i>Brain Communications</i> , 2021, 3, fcb222.	3.3	53
505	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	2.1	230

#	ARTICLE	IF	CITATIONS
506	Primary cells derived from Tuberous Sclerosis Complex patients show autophagy alteration in the haploinsufficiency state. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200475.	1.3	0
507	Glioma stem cells, plasticity, and potential therapeutic vulnerabilities. , 2021, , 83-102.		0
508	Pediatric Central Nervous System Cancer Predisposition. , 2021, , 23-54.		1
509	Upfront treatment with <scp>mTOR</scp> inhibitor everolimus in pediatric low-grade gliomas: A single-center experience. <i>International Journal of Cancer</i> , 2021, 148, 2522-2534.	5.1	19
510	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345.	0.2	1
511	Pediatric Low-Grade Gliomas: Diagnosis, Treatment, and Future Directions. <i>Tumors of the Central Nervous System</i> , 2015, , 13-24.	0.1	1
512	Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. <i>World Neurosurgery</i> , 2017, 107, 1053.e1-1053.e6.	1.3	11
513	Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. <i>Journal of Clinical Investigation</i> , 2016, 127, 349-364.	8.2	49
514	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e395-e401.	3.8	67
515	Stochastic Model of Tsc1 Lesions in Mouse Brain. <i>PLoS ONE</i> , 2013, 8, e64224.	2.5	16
516	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. <i>PLoS ONE</i> , 2016, 11, e0158476.	2.5	146
517	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. <i>PLoS ONE</i> , 2017, 12, e0186235.	2.5	10
518	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e395-e401.	3.8	51
519	Tuberous Sclerosis Complex: A Roadmap for Future Research. <i>Pediatric Neurology Briefs</i> , 2016, 30, 32.	0.2	2
520	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. <i>Oncotarget</i> , 2017, 8, 64714-64727.	1.8	18
521	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. , 2019, 2, 1069-1085.		11
522	Antiepileptic Drugs in Clinical Development: Differentiate or Die?. <i>Current Pharmaceutical Design</i> , 2018, 23, 5593-5605.	1.9	8
523	Therapeutic Targeting of Cancers with Loss of PTEN Function. <i>Current Drug Targets</i> , 2014, 15, 65-79.	2.1	194

#	ARTICLE	IF	CITATIONS
524	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	2.9	64
525	Bilateral renal angiomyolipomas and subependymal giant cell astrocytoma associated with tuberous sclerosis complex: A case report and review of the literature. Balkan Journal of Medical Genetics, 2021, 23, 93-98.	0.5	2
526	Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors. World Journal of Gastroenterology, 2014, 20, 15920.	3.3	2
527	Subependymal giant cell astrocytoma: Associated hyperproteinorrachia causing shunt failures and nonobstructive hydrocephalus - Report of successful treatment with long-term follow-up. Journal of Innovative Optical Health Sciences, 2017, 12, 746.	1.0	3
529	Impact of genetic alterations on mTOR-targeted cancer therapy. Chinese Journal of Cancer, 2013, 32, 270-274.	4.9	8
530	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	4.9	253
531	Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex. Respiratory Medicine Case Reports, 2021, 34, 101526.	0.4	2
532	Precision Therapy for Epilepsy Related to Brain Malformations. Neurotherapeutics, 2021, 18, 1548-1563.	4.4	18
533	Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 111-119.	2.0	5
534	Cardiometabolic consequences of targeted anticancer therapies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	3
535	Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. Epilepsia, 2021, 62, 3029-3041.	5.1	16
536	Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 737670.	3.7	2
537	Renal Cell Carcinoma in Tuberous Sclerosis Complex. Genes, 2021, 12, 1585.	2.4	33
538	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
539	Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans. Clinical Investigation, 2013, 3, 637-650.	0.0	0
540	Neuroonkologie. , 2014, , 277-304.		0
542	Neurokutane Erkrankungen. , 2014, , 83-110.		0
543	Targeted Therapies in Paediatric Brain Tumours. , 2015, , 217-226.		0

#	ARTICLE	IF	CITATIONS
544	Gliome niedrigen Malignitätsgrades im Kindes- und Jugendalter. , 2015, , L6f.1-L6f.15.		0
545	Management of Subependymal Giant Cell Astrocytomas in Patients with Tuberous Sclerosis. Journal of the Korean Child Neurology Society, 2015, 23, 1-6.	0.0	0
546	General aspects of aetiology, diagnostics and therapy. , 2016, , 3-104.		0
547	Chemotherapy and Novel Cancer Targeted Therapies. , 2016, , 135-152.		0
548	Tumour suppressor/DNA-repair disorders. , 2016, , 193-254.		0
549	Efficacy of Everolimus for Rhabdomyoma Associated with Tuberous Sclerosis Complex. Nihon Shoni Jinkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2016, 32, 445-447.	0.0	0
550	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.0	1
551	Surendra Nath Sehgal: A pioneer in rapamycin discovery. Indian Journal of Cancer, 2017, 54, 697.	0.2	5
552	Cutaneous Reactions to Targeted Anticancer Agents. , 2018, , 139-153.		0
553	ZNS-Tumoren. , 2018, , 359-418.		2
554	Familial Syndromes. , 2018, , 1-55.		0
555	Familial Syndromes. , 2018, , 1-54.		0
557	PARTICIPATION OF A PRIMARY PEDIATRICIAN IN THE EARLY DIAGNOSTICS AND TREATMENT OF TUBEROUS SCLEROSIS IN CHILDREN. Rossiyskiy Vestnik Perinatologii i Pediatrii, 2018, 63, 222-230.	0.3	2
559	Promises of targeted therapy for low grade gliomas in children. Uspehi Molekularnoj Onkologii, 2019, 6, 28-41.	0.3	1
560	Experience of a Single Center in Treating Multiple Manifestations of Tuberous Sclerosis Complex with Everolimus. Annals of Child Neurology, 2019, 27, 135-145.	0.1	1
561	Evolution in the Management of Childhood Low-Grade Gliomas and Neuronal/Mixed Neuronal-Glial Tumors. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 105-108.	0.3	0
562	Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82.		0
563	Anticonvulsant Agents: Everolimus. , 2020, , 1-32.		0

#	ARTICLE	IF	CITATIONS
564	Familial Syndromes. , 2020, , 1793-1834.		0
565	Rare inherited kidney diseases: an evolving field in Nephrology. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 219-230.	0.9	3
566	Renal Manifestations of Tuberous Sclerosis Complex. Journal of Kidney Cancer and VHL, 2020, 7, 5-19.	1.0	16
567	Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. Journal of Urology, 2020, 204, 531-537.	0.4	9
568	Abdominal ultrasonographic manifestations in pediatric patients with tuberous sclerosis complex. Translational Pediatrics, 2020, 9, 757-767.	1.2	1
570	PTEN inhibitor VOâ€™OHpic suppresses TSC2â€™/â€™ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Experimental and Therapeutic Medicine, 2020, 19, 3565-3570.	1.8	2
571	Trends in survival and treatment of SEGA: National Cancer Database Analysis. Neuro-Oncology Practice, 2021, 8, 98-105.	1.6	1
573	Hypermethylation of the Promoter of miR-338-5p Mediates Aberrant Expression of ETS-1 and Is Correlated With Disease Severity Of Astrocytoma Patients. Frontiers in Oncology, 2021, 11, 773644.	2.8	6
574	Novel treatments in epilepsy guided by genetic diagnosis. British Journal of Clinical Pharmacology, 2022, 88, 2539-2551.	2.4	8
575	Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. Frontiers in Medicine, 2021, 8, 744050.	2.6	3
576	Early Vascular Aging in Children With Tuberous Sclerosis Complex. Frontiers in Pediatrics, 2021, 9, 767394.	1.9	1
577	Targeted Therapies for the Neurofibromatoses. Cancers, 2021, 13, 6032.	3.7	13
578	Mechanistic Target of Rapamycin (mTOR) Inhibitors. Handbook of Experimental Pharmacology, 2021, , 53-72.	1.8	6
579	Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Journal of Clinical Medicine, 2022, 11, 249.	2.4	3
580	New and emerging pharmacologic treatments for developmental and epileptic encephalopathies. Current Opinion in Neurology, 2022, 35, 145-154.	3.6	8
581	A Balance Between Autophagy and Other Cell Death Modalities in Cancer. Methods in Molecular Biology, 2022, 2445, 3-24.	0.9	0
582	Treatment of Aggressive Retinal Astrocytic Hamartoma with Oral Mechanistic Target of Rapamycin Inhibition. Ophthalmology Retina, 2022, 6, 411-420.	2.4	7
583	Global management of brain metastasis from renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2022, 171, 103600.	4.4	2

#	ARTICLE	IF	CITATIONS
585	Multiple intracardiac benign tumors treated with low-dose everolimus. , 2022, 26, 141-142.		0
586	A farnesyltransferase inhibitor restores cognitive deficits in Tsc2+/- mice through inhibition of Rheb1. Journal of Neuroscience, 2022, , JN-RM-0449-21.	3.6	3
587	Renal Involvement in Tuberous Sclerosis Complex. , 2021, , 1-12.		0
588	COVID 19 in a family with rare genetic disease of the nervous system. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 108-114.	1.2	3
589	Managing Headache Disorders Associated with Tuberous Sclerosis and Neurofibromatosis. Current Pain and Headache Reports, 2022, 26, 281-288.	2.9	2
590	Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2022, 17, 106.	2.7	23
591	Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipomas. Frontiers in Oncology, 2022, 12, 852859.	2.8	2
592	Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results. Frontiers in Pharmacology, 2022, 13, 802334.	3.5	8
593	A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant. Respiratory Medicine, 2022, 195, 106779.	2.9	1
594	Bi-allelic variants in OGDHL cause a neurodevelopmental spectrum disease featuring epilepsy, hearing loss, visual impairment, and ataxia. American Journal of Human Genetics, 2021, 108, 2368-2384.	6.2	12
595	Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neuro-Oncology Advances, 0, , .	0.7	3
602	Progress in Tuberous Sclerosis Complex Renal Disease. Critical Reviews in Oncogenesis, 2022, 27, 35-49.	0.4	2
603	Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2022, 13, 704978.	2.4	4
604	Monitoring and Managing Patients with Tuberous Sclerosis Complex: Current State of Knowledge. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1469-1480.	2.7	2
606	Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors. Neurochirurgie, 2022, 68, 627-636.	1.2	2
607	Characteristics and trends of globally registered glioma clinical trials in the past 16 years. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211143.	3.5	1
608	Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort. Journal of Neurosurgery: Pediatrics, 2022, 30, 316-329.	1.3	3
609	Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 2022, 14, 4059.	3.7	31

#	ARTICLE	IF	CITATIONS
610	Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex. Nature Communications, 2022, 13, .	12.8	17
611	A clinical challenge case of bilateral giant renal angiomyolipoma associated with tuberous sclerosis complex. Urology, 2022, , .	1.0	0
612	Cystic Diseases of the Kidney. , 2023, , 39-94.		1
613	LysM-positive neurons drive Tuberous Sclerosis Complex (TSC)-associated brain lesions. Cellular Signalling, 2022, 100, 110468.	3.6	0
614	Successful treatment with everolimus for severe heart failure with large cardiac rhabdomyomas. Pediatrics International, 2022, 64, .	0.5	2
615	Renal Involvement in Tuberous Sclerosis Complex. , 2022, , 1213-1224.		0
616	Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	2
618	Nervous system (NS) Tumors in Cancer Predisposition Syndromes. Neurotherapeutics, 2022, 19, 1752-1771.	4.4	4
620	An approach to the tuberous sclerosis complex. International Journal of Research in Medical Sciences, 2022, 10, 2320.	0.1	0
621	Construction of TSC2 knockout cell line using CRISPR/Cas9 system and demonstration of its effects on NIH-3T3 cells. Cell Biochemistry and Biophysics, 0, , .	1.8	0
622	Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. JCO Precision Oncology, 2022, , .	3.0	7
624	Lung transplantation for lymphangioleiomyomatosis. Journal of Heart and Lung Transplantation, 2023, 42, 40-52.	0.6	1
625	Management of Renal Angiomyolipomas in Tuberous Sclerosis Complex: A Case Report and Literature Review. Journal of Clinical Medicine, 2022, 11, 6084.	2.4	1
626	Anti-convulsant Agents: Everolimus. , 2022, , 3721-3751.		0
627	Bcl-2, JAK and mTOR Inhibitors. , 2022, , 293-313.		0
628	Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study. Neurolmage: Clinical, 2023, 37, 103288.	2.7	0
629	MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor. International Journal of Molecular Sciences, 2022, 23, 14493.	4.1	0
631	Low grade gliomas guide-lines elaborated by the tumor section of Spanish Society of Neurosurgery. NeurocirugAa (English Edition), 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
632	Shared mechanisms of neural circuit disruption in tuberous sclerosis across lifespan: Bridging neurodevelopmental and neurodegenerative pathology. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	3
633	Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 214-222.	5.6	7
634	Effect of different dose regimens of everolimus in a series of neonates with giant cardiac rhabdomyomas. <i>Cardiology in the Young</i> , 0, , 1-6.	0.8	0
635	Tuberous Sclerosis Complex Kidney Lesion Pathogenesis: A Developmental Perspective. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 1135-1149.	6.1	0
636	Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex—Current Views on Their Pathogenesis and Management. <i>Journal of Clinical Medicine</i> , 2023, 12, 956.	2.4	0
637	Phase II study of everolimus for recurrent or progressive pediatric ependymoma. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	0
638	Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	1
639	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664.	4.5	2
640	UPLC-MS based integrated plasma proteomic and metabolomic profiling of TSC-RAML and its relationship with everolimus treatment. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	0
641	Glioblastoma and Other Primary Brain Malignancies in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 574.	7.4	123
642	Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. , 2023, 2, 114-130.		0
643	Treatment of Pediatric Low-Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 185-199.	4.2	5
644	Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan. <i>Dermatology and Therapy</i> , 0, , .	3.0	0
645	Upregulation of acid ceramidase contributes to tumor progression in Tuberous Sclerosis Complex. <i>JCI Insight</i> , 0, , .	5.0	0
647	Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases. <i>Diagnostics</i> , 2023, 13, 1232.	2.6	0
648	Bcat1 is controlled by Tsc2/ ^{mTORC1} pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a ^{Tsc2} tumor cell line. <i>Genes To Cells</i> , 0, , .	1.2	0
649	Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. , 2023, , 147-200.		1
650	Neurokutane Syndrome. , 2023, , 159-178.		0

#	ARTICLE	IF	CITATIONS
651	New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis. <i>Biomedicine and Pharmacotherapy</i> , 2023, 163, 114806.	5.6	3
652	Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
653	Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19.		0
654	Evolving Diagnostic and Treatment Strategies for Pediatric CNS Tumors: The Impact of Lipid Metabolism. <i>Biomedicines</i> , 2023, 11, 1365.	3.2	0
655	Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	3.8	6
656	The flaws in assessing and reporting the toxicities of oral targeted therapies. <i>Seminars in Oncology</i> , 2023, 50, 1-6.	2.2	0
657	Rapamycin and rapalogs for tuberous sclerosis complex. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	3
658	Benign Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 31-71.	1.6	0
659	Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus. <i>Pharmacological Research</i> , 2023, 195, 106884.	7.1	2
661	Cardiac self-limiting rhabdomyomas in a neonatal patient with tuberous sclerosis complex: a case report with negative genetic testing. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	0
662	Tuberous Sclerosis Complex. <i>Keio Journal of Medicine</i> , 2023, , .	1.1	1
663	Bilateral renal angiomyolipoma with left renal artery aneurysm in tuberous sclerosis: case report and literature review. <i>Annals of Medicine and Surgery</i> , 2023, 85, 5113-5116.	1.1	2
664	Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. <i>Pharmacogenomics</i> , 2023, 24, 731-738.	1.3	2
665	Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
666	Molecular Profiling and Targeted Therapies in Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 627-636.	4.2	2
667	A Molecular Update and Review of Current Trials in Paediatric Low-Grade Gliomas. <i>Pediatric Neurosurgery</i> , 0, , 1-9.	0.7	0
668	Neurological and Dermatological Manifestations of Tuberous Sclerosis Complex: Report from a Romanian Tertiary Hospital Cohort. <i>Journal of Clinical Medicine</i> , 2023, 12, 6550.	2.4	0
669	Epilepsy in gliomas: recent insights into risk factors and molecular pathways. <i>Current Opinion in Neurology</i> , 0, , .	3.6	0

#	ARTICLE	IF	CITATIONS
670	<scp>SEGA</scp>â€like circumscribed astrocytoma in a <scp>nonâ€NF1</scp> patient, harboring molecular profile of <scp>GBM</scp>. A case report. Neuropathology, 0, , .	1.2	0
671	An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients. Child's Nervous System, 2024, 40, 823-829.	1.1	0
672	Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia. Frontiers in Pharmacology, 0, 14, .	3.5	0
673	Screening and management of metabolic complications of mTOR inhibitors in real-life settings. Annales D'Endocrinologie, 2023, , .	1.4	0
674	Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Orphanet Journal of Rare Diseases, 2023, 18, .	2.7	1
675	Cerebral vascular and blood brainâ€barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex. Epilepsia, 2024, 65, 483-496.	5.1	1
676	Incidental Brain Tumors. , 2023, , 71-87.		0
677	Imaging of supratentorial intraventricular masses in children: a pictorial reviewâ€”part 2. Neuroradiology, 0, , .	2.2	0
678	A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimerâ€™s Disease and Other Neurological Disorders. International Journal of Molecular Sciences, 2023, 24, 17478.	4.1	0
679	Treatment of tuberous sclerosis complex-associated retinal astrocytic hamartoma complicated with vitreous hemorrhage. Indian Journal of Ophthalmology Case Reports, 2023, 3, 1081-1086.	0.1	0
680	Cancer Predisposition Syndromes in Neuro-Oncology. Seminars in Neurology, 0, , .	1.4	0
681	Macrolides for Cancer. , 2024, , 223-254.		0
682	Early Post-Natal Immune Activation Leads to Object Memory Deficits in Female Tsc2+/â€ Mice: The Importance of Including Both Sexes in Neuroscience Research. Biomedicines, 2024, 12, 203.	3.2	0
683	Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356.		0
684	Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of Neuro-Oncology, 2024, 167, 339-348.	2.9	0
685	Case Report: Tuberous sclerosis complex-associated hemihypertrophy successfully treated with mTOR inhibitor sirolimus. Frontiers in Pediatrics, 0, 12, .	1.9	0
686	Cardiac Rhabdomyomas Presenting with Critical Cardiac Obstruction in Neonates and Infants: Treatment Strategies and Outcome, A Single-Center Experience. Pediatric Cardiology, 2024, 45, 1132-1141.	1.3	0
687	Resultados Perinatais e Seguimento em Longo Prazo de Tumores CardÃ¡acos Fetais: Estudo de Coorte HistÃ³rica de 30 Anos. Arquivos Brasileiros De Cardiologia, 2024, 121, .	0.8	0